Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer has now fully entered the era of immunotherapy. Immunotherapy‐based treatment has become one of the standard treatments for lung cancer. Immunotherapy has also gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.

Radiotherapy is one of the main tumor treatment modalities that provides great survival benefits to patients with cancer. However, it is important to pay attention to the occurrence of adverse events after radiotherapy and take early measures. Radiation pneumonitis (RP) is a major adverse response in patients with cancer receiving thoracic radiotherapy, and it affects the quality of life and survival of patients. We analyzed the latest evidence on RP, and summarized research developments on the pathophysiological mechanism, risk factors, clinical manifestations, diagnosis and differential diagnosis, classification, treatment, and prognosis to form a consensus. With the development of comprehensive treatments, including immunotherapy, the diagnosis and identification of RP has become more complex, requiring multidisciplinary discussion and decision-making. In the future, it is critical to explore more effective treatments, various risk factors, and precautions for RP.